Tarlatamab Administration and Postinfusion Monitoring

Summary for Physicians:

Tarlatamab Administration:

• Route: Intravenous (IV) infusion
• Initial dosing: Start with lower doses to monitor for adverse effects, gradually increasing as tolerated.
• Infusion schedule: IMDELLTRA is administered as a 1-hour IV infusion every two weeks (Q2W) following an initial step-up dosing schedule. Patients should be monitored for 22–24 hours from the start of the infusion in an appropriate healthcare setting.

Monitoring Protocol Post Infusion:

• Immediate monitoring:
• Patients are observed for 1 to 2 hours post infusion to monitor for acute reactions such as cytokine release syndrome (CRS).

• Monitoring includes vital signs, oxygen saturation, and symptoms of infusion-related reactions.
• Ongoing monitoring:
• Regular follow-up visits (usually 24-48 hours post infusion) to assess for delayed adverse effects.

• Patients are educated on self-monitoring for symptoms such as fever, chills, or shortness of breath.

• Continuous assessment for immune-related toxicities.

Challenges:

Ensuring timely detection of CRS or other adverse events and having adequate support for emergency interventions.